Radioactive drug plus immunotherapy for FAP-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with advanced non-small cell lung cancer that has spread to other parts of your body.
- A special PET scan called FAPI PET shows that your tumors have a protein called FAP.
- You are generally in good health and can walk around and take care of yourself (ECOG score 0 or 1).
- You have not had certain other treatments (like chemotherapy or immunotherapy) in the past 3 weeks, or certain radiation in the past 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
This trial is testing an investigational drug called 177Lu-FAP-VG1 for people with advanced solid tumors that have stopped responding to standard therapy. The drug is a type of radiation therapy that targets a protein called FAP, which is found on many cancer cells, to try to shrink the tumor and slow the cancer's growth.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This trial tests a new radioactive drug (177Lu-FAP-2286) for advanced bladder cancer that has stopped responding to standard treatments. The drug targets a protein on the cancer cells to deliver radiation directly to them, with the goal of shrinking tumors and controlling the disease.
This trial tests a special radioactive medicine (177Lu-CTR-FAPI) for people with advanced digestive cancers that have high FAP expression. The medicine targets a protein on cancer cells to deliver radiation directly to tumors, potentially slowing their growth.
Hear when a new Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.